We could demonstrate that it is feasible to reduce sputum eosinophilia in the sputum eosinophil-high subgroups of COPD patients inhaling the GATA3-specific DNAzyme SB010 over a period of 4 weeks. This evidence concerns the gene GATA3 and chronic obstructive pulmonary disease.